english.mathrubhumi4d
Explainer: What is Guillain-Barré Syndrome and how it affects the immune system
Guillain-Barré Syndrome (GBS) is a rare neurological disorder where the immune system attacks nerves. Learn about symptoms, ...
Mid Day3d
What is Guillain-Barré Syndrome? Know when to seek treatment and how to prevent it
Tingling, weakness of hand-grip or foot drop could signal Guillain-Barré Syndrome (GBS), said health experts on Monday, even ...
Guillain Barre Syndrome (GBS): Symptoms causes treatment prevention
Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder where the immune system attacks peripheral nerves, causing ...
GBS cases rise: What are key symptoms? Is it deadly? Can it be treated? Here is all about the syndrome
A 40-year-old man suspected of having Guillain-Barre Syndrome (GBS) died in Solapur, Maharashtra. Over 100 cases of GBS have ...
What triggers Guillain-Barré syndrome?
Guillain-Barré syndrome is rare. The cause of it is not fully known, but most cases follow an infection with a virus or ...
Guillain-Barré Syndrome: 5 deadly symptoms of this severe neurological condition spreading in India
Guillain-Barré Syndrome (GBS) is a rare neurological condition that causes muscle weakness and can lead to paralysis. Linked ...
pharmaphorum1y
FDA gives Pfizer's Group B strep vaccine breakthrough status
On the strength of phase 2 data, the FDA has awarded coveted breakthrough status to Pfizer's vaccine against Group B Streptococcus (GBS), given to expectant mothers to prevent invasive infections ...
Yahoo Finance1mon
Hansa Biopharma announces success in Guillain-Barré Syndrome trial
Swedish biotechnology firm Hansa Biopharma has announced that its investigational drug imlifidase improved motor function in patients with Guillain-Barré Syndrome (GBS) in a Phase II study.
What is Guillain-Barre Syndrome, rare disorder behind 1 death, over 100 cases in Pune?
The Maharashtra government noted that high number of cases in certain areas appears to be linked to suspected water ...
Nasdaq1mon
Annexon (ANNX) Surges with Promising Phase 3 Results for Guillain-Barré Syndrome Treatment
Further, ANX009 is in Phase I clinical trial for treating lupus ... the company’s progress in priority programs, including GBS, GA, and ANX1502. G&A expenses also increased, reaching $9.3 ...